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Objective. To retrospectively evaluate ANCA testing in a cohort of unselected Greek in- and outpatients. Methods. In 10803
consecutive serum samples, ANCA were tested by indirect immunoﬂuorescence (IIF) and ELISA. ELISA in inpatients was
performed only on IIF positive sera. Results. Low prevalence (6.0%) of IIF positive samples was observed. Among these samples,
63.5% presented perinuclear (p-ANCA), 9.3% cytoplasmic (c-ANCA) and 27.2% atypical (x-ANCA) pattern. 16.1% of p-ANCA
were antimyeloperoxidase (anti-MPO) positive, whereas 68.3% of c-ANCA were antiproteinase-3 (anti-PR3) positive. Only 17
IIF negative outpatients’ samples were ELISA positive. ANCA-associated vasculitides (AAV), connective tissue disorders and
gastrointestinaldisordersrepresented 20.5%,23.9%,and21.2%ofpositiveresults,respectively. AAVpatientsexhibited higherrates
of MPO/PR3 speciﬁcity compared to non-AAV (93.8% versus 8%). Conclusions. This ﬁrst paper on Greek patients supports that
screening for ANCA by IIF and conﬁrming positive results by ELISA minimize laboratory charges without sacriﬁcing diagnostic
accuracy.
1.Introduction
Antineutrophil cytoplasmic antibodies (ANCA) are autoan-
tibodies directed against constituents of primary granules
of neutrophils and monocytes lysosomes [1]. Since the ﬁrst
description of ANCAs in 1982 in patients with necrotizing
glomerulonephritis [2], ANCA testing currently plays a crit-
ical role in diagnosis and monitoring of a subgroup of vas-
culitides, referred as ANCA-associated vasculitides (AAV):
Wegener’s granulomatosis (WG), microscopic polyangiitis
(MPA) and Churg-Strausssyndrome (CSS)[1, 3, 4]. Indirect
immunoﬂuorescence (IIF) and ELISA remain the most
widely used techniques for ANCA detection. Using IIF on
ethanol-ﬁxed neutrophils, three patterns are recognized:
diﬀuse cytoplasmic staining (c-ANCA), perinuclear staining
(p-ANCA) and atypical staining (x-ANCA) [5]. Among
several antigenic targets described, only antibodies targeting
proteinase 3 (anti-PR3) and myeloperoxidase (anti-MPO)
are of clinical value [6]. c-ANCA mainly target PR3 and
are often observed in WG patients, while p-ANCA predom-
inantly bind to MPO and are common in patients with
MPA and CSS [1]. However, ANCAs have been reported
in a number of other conditions including infections,
malignancies, connective-tissue diseases, renal diseases, and
other vasculitides and gastrointestinal disorders [1, 5, 6].
It is believed that genetic susceptibility (e.g., polymor-
phisms of HLA, FcγR, IL-10, a1-antitrypsin genes) and
various environmental factors (e.g., infections, medication,
silica, and climate)are implicated in the induction of ANCA.
Diﬀerencesin distribution ormagnitude ofthese factors lead
to geographical, ethnic, regional and seasonalvariations in
the epidemiological characteristics of AAV [7, 8]. In this
context, Greek patients with autoimmune diseases and AAV
present signiﬁcant genetic diﬀerences as compared to other
Caucasians [9–12].
Although, several studies evaluating ANCA testing have
been reported [13–21], those that evaluate the clinical value
of ANCA under actual routine conditions in unselected2 Autoimmune Diseases
patients are rather rare [13–16]. Moreover, few data regard-
ing Greek population are available [12, 22]. Thus, the aim
of this large retrospective study was (i) to determine the
frequency of ANCA in a cohort of unselected consecutive
in- and outpatients of a tertiary care hospital, where patients
from all over Greece are referred, (ii) to analyze the results
of ANCA testing taking into consideration clinical features,
histopathological characteristics and ﬁnal diagnoses, and
ﬁnally (iii) to evaluate the two diﬀerent strategies that have
been adopted in our institution, in order to establish an
algorithm on ANCA detection that ensures low laboratory
charges with maximal diagnostic accuracy.
2.PatientsandMethods
This study was approved by the Greek Authority of Personal
Data Protection. The study population included 10803
patients of Greek ethnicity, that underwent ANCA testing
from September 2003 to August 2006, at “Evangelismos”
General Hospitalof Athens. This is the largesttertiary health
care center of Greece (863 beds) that serves all geographical
locationsofthecountry.Outof10803patients,6342(58.7%)
were female and 4461 (41.3%) were male. The mean age of
the tested population was 52.1 (range 10–95) years old.
Atotalof6017serumsamplesfromdiﬀerentdepartments
(nephrology,neurology,gastroenterology, internal medicine,
respiratory medicine and others) and 4786 serum sam-
ples from the outpatient clinics, were submitted to the
Immunology-Histocompatibility Department, with a test
requestforANCA.Forinpatients, IIFwasinitiallyperformed
and ELISA,for antibodies toPR3 and MPO, was additionally
used in all IIF positive sera. On the other hand, a parallel
testing that included both IIF and ELISA was applied to all
outpatients.
2.1. ANCA Detection Methods. Indirect immunoﬂuores-
cence (IIF) was performed on commercially prepared
neutrophil substrate slides, ﬁxed with ethanol (ANCA
kit/substrate slides, The Binding Site). Sera titration ranged
from 1/20 to 1/640. Titres ≥ 1/20 were considered posi-
tive.For the detection of MPO-ANCA and PR3-ANCA com-
mercially available ELISA kits (QUANTA Lite MPO/PR3,
INOVA diagnostics) were used. The results were recorded as
positive when MPO/PR3 ANCA levels were ≥20U.
2.2. Diagnostic Classiﬁcation. ANCA positive results were
correlated with the patients’ diagnoses, as established by
their treating physician at the time of sampling. Physi-
cians makingthe diagnoses were a diverse group of clin-
iciansincluding nephrologists, neurologists, gastroenterolo-
gists, pneumonologists and oncologists. The medical ﬁles
of patients were carefully reviewed by two of the authors
(K. Tsiveriotis and A. Tsirogianni). In discrepant cases, a
consensus with the patients’ treating physician took place.
The following disease categories were deﬁned: (1) AAV, (2)
connective tissue diseases, (3) gastrointestinal disorders, (4)
other vasculitides, (5) infections, (6) neurological disorders,
(7) malignancies, (8) renal diseases, (9) medication, (10)
miscellaneous disorders, and (11) undiagnosed cases. The
speciﬁc conditions that were included in each disease cate-
gory and the diagnostic criteria that were used to adjudicate
cases are presented in Table 1.
2.3. Statistical Analysis. For the comparison of IIF titers and
ELISA levels between AAV and non-AAV patients, a chi-
square test and a t-test were used, respectively. P values <. 05
were considered statistically signiﬁcant.
T h ep o s i t i v ep r e d i c t i v ev a l u e( P P V )o fA N C At e s t i n gf o r
AAV was estimated, deﬁned as the percentage of positive
patientswho had thedisease: (truepositives ÷(truepositives
+ false positives) × 100). The 95% conﬁdence intervals (CI)
were determined.
3.Results
From September 2003 to August 2006, 10803 sera sam-
ples of Greek patients were screened in Immunology-
Histocompatibility Department of “Evangelismos” General
Hospital, for the presence of ANCA. The majority of them
(10142/10803—93.9%)were found negative by both IIF and
ELISAandonly661(6.1%)werefoundpositivebyIIFand/or
ELISA. Among positive samples, 288 (43.6%) derived from
outpatients, whereas 373 (56.4%) derived from hospitalized
patients.Out of 661 ANCA positive patients, 441 (62.0%)
were female and 251 (38.0%) were male. The mean age was
60.1 (range 19–95) years old.
The results obtained by IIF and ELISA are presented in
Table 2. p-ANCA pattern predominated among IIF-positive
patients (409/644—63.5%). The majority of p-ANCA pos-
itive sera were testednegative for both anti-MPO and anti-
PR3 (339/409—82, 9%). Eighty sera were testedanti-MPO
positive, 66 (82.5%) of which were also p-ANCA positive.
Sixty sera (9.3%) showed c-ANCA pattern, 41 (68.3%) with
speciﬁcity for PR3 and none for MPO. Among the 175
(27.2%)x-ANCA,157(89.7%)wereELISAnegative,whereas
10 were presented anti-MPO and 8 anti-PR3 positive. As all
outpatients’ sera were screened by both IIF and ELISA, a
small number(17)werefoundIIF(−)/ELISA(+),13ofthem
were positive for anti-PR3 and 4 positive for anti-MPO.
The relationship between the results of ANCA testing
and clinical diagnosis is shown in Table 3.T h i sa n a l y s i s
included 552 patients, 109 excluded due to insuﬃcient
data. ANCA-associated vasculitides (AAV) represented only
20.5% (113/552) of positive results. This group included
microscopic polyangiitis, Wegener’s granulomatosis, Churg-
Strauss syndrome and the localized forms of these diseases.
The majority of AAV patients with ANCA, were found
positive by ELISA (106/113—93.8%). In particular, most
MPA and CSS patients exhibited p-ANCA/MPO-ANCA
positivity (67.2% and 66.7%, resp.), whereas Wegener’s
granulomatosis was closely associated with c-ANCA/PR3-
ANCA (73.9%).
The majority (79.5%) of positive sera derived from
non-AAV patients. The most common disease categories
were connective tissue disorders (132/552—23.9%) and gas-
trointestinal disorders (117/552—21.2%). However, severalAutoimmune Diseases 3
Table 1: Diseases and diagnostic criteria.
ANCA-associated vasculitides (AAV)
Microscopic polyangiitis (MPA) Chapel Hill Consensus Conference nomenclature [23]
Wegener’s granulomatosis (WG) ACR Classiﬁcation Criteria for WG [24]
Churg-Strauss syndrome (CSS) ACR Classiﬁcation Criteria for CSS [25]
Other vasculitides
Polyarteritis nodosa (PAN) ACR Classiﬁcation Criteria for PAN [26]
Behc ¸et’sdisease(BD) International Criteria for BD [27]
Henoch-Sch¨ onlein purpura (HSP) ACR Classiﬁcation Criteria for HSP [28]
Cryoglobulinemic vasculitis Chapel Hill Consensus Conference nomenclature [23]
Secondary vasculitis Diagnostic criteria of underlying disease, histologicalconﬁrmation
Undeﬁned vasculitis Clinical features without histological conﬁrmation
Gastrointestinal disorders (GD)
Inﬂammatory bowel disease (IBD) Clinical, endoscopic, radiological and histological criteria [29]
Primary sclerosing cholangitis Clinical, radiological and immunologicalcriteria [30]
Autoimmune hepatitis (AIH) International Criteria for AIH [31]
Primary biliary cirrhosis Clinical, biochemical, immunologicaland histological criteria [32]
Connective tissue diseases (CTD)
Systemic lupus erythematosus (SLE) Updated revised ACR Criteria for SLE [33]
Rheumatoid arthritis (RA) Revised ARA criteria for RA [34]
Felty’s syndrome Clinical, radiological and laboratory criteria [35]
Systemic sclerosis (SSc) ARA preliminary classiﬁcation Criteria for SSc [36]
Dermatomyositis (DM) Bohan and Peter diagnostic Criteria for DM [37, 38]
Sj¨ ogren’s syndrome (SjS) Revised International ClassiﬁcationCriteria for SjS [39]
Mixed connective tissue disease (MCTD) Alarcon-Segovia Diagnostic Criteria for MCTD [40]
Reiter’s syndrome Clinical, radiological and immunologicalcriteria [41]
Ankylosing spondylitis Clinical, radiological and immunologicalcriteria [42]
Juvenile chronic arthritis Clinical, radiological and immunologicalcriteria [43]
Relapsing polychondritis Clinical, radiological and histological criteria [44]
Psoriasis Clinical features
Antiphospholipid syndrome Clinical and laboratory criteria [45]
Rheumatic polymyalgia Clinical features and laboratory ﬁndings
Infections
Tuberculosis (TBC)
S. aureus (subacute endocarditis)
Other bacterial infections Clinical features and laboratory ﬁndings
AIDS
Hepatitis C
Aspergillosis
Renal diseases (RD)
Poststreptococcal nephropathy (PSGN)
IgA nephropathy Laboratory and immunologicalﬁndings, histologicalconﬁrmation
Goodpasture’s disease
Membranous nephropathy
Malignancies
Carcinoma
Lymphoma
Clinical features, laboratory ﬁndings, histological conﬁrmation Chronic myelocytic leukaemia
Myelodysplasia
Monoclonalgammopathies4 Autoimmune Diseases
Table 1: Continued.
ANCA-associated vasculitides (AAV)
Neurological disorders (ND)
Demyelinating disease
Stroke Neurological symptoms and imaging ﬁndings
Miscellaneous disorders
Sarcoidosis Clinical features, laboratory and imagingﬁndings
Autoimmune hemolytic anemia (AHA) Clinical features and laboratory ﬁndings
Pulmonary ﬁbrosis Imaging ﬁndings, histologicalconﬁrmation
Medication
Antithyroid drugs
Allopurinol History of medication treatment
Phenytoin
Table 2: Relationship between IIF pattern and ELISA test results.
IIF results Anti-MPO positive Anti-PR3 positive Anti-MPO/anti-PR3 negative Total (N)
p-ANCA N 66 4 339 409
% 16.14 0.98 82.89
c-ANCA N 04 1 1 960
% 0.00 68.33 31.67
x-ANCA N 10 8 157 175
% 5.71 4.57 89.71
Negative N 4 13 10142 10159
% 0.04 0.13 99.83
Total N 80 66 10657 10803
% 0.74 0.61 98.65
other conditions were recognized such as other vasculi-
tides (39/552—7.0%), infections (36/552—6.5%), neuro-
logical diseases (33/552—6.0%), malignancies (31/552—
5.6%), renal disease (22/552—4%), medication (15/552—
2.7%), and miscellaneous disorders (14/552—2.6%). p-
ANCA, followed by x-ANCA, was the predominant IIF
pattern in the non-AAV group, whereas, unlike vasculitic
group, the majority (404/439—92.0%) of positive sera were
tested negative by ELISA. However, in 35 samples (8%) of
this group, anti-MPO or anti-PR3 antibodies were detected.
The spectrum of diseases that were associated with anti-
MPO antibodies included secondary vasculitides (6/22),
SLE (6/22), RA (3/22), TBC (2/22), AIH (1/22), undeﬁned
vasculitis (1/22), PSGN (1/22), multiple myeloma (1/22),
and Goodpasture’s syndrome (1/22). On the other hand,
ulcerative colitis (UC) (7/13), Crohn’s disease (CD) (1/13),
PAN (1/13), Henoch-Sch¨ onlein purpura (1/13), undeﬁned
vasculitis (1/13), psoriasis (1/13) and AHA (1/13) were
associated with anti-PR3 antibodies.
In AAV patients statistically signiﬁcant higher IIF titers
were observed, compared to non-AAV (chi-square test, P<
.001).Speciﬁcally,57%ofIIFpositivesera exceeded1/80titer
versus 35% in non-AAV patients. Moreover, diﬀerence in
anti-PR3 levels between AAV and non-AAV patients (58.8 ±
32.4U versus 35.9 ± 17.2U) were also statistically signiﬁcant
(one tailed t-test, P = .001). On the other hand, the
respective comparison in anti-MPO (52.6 ± 24.5U versus
43.2 ± 22.5U) did not achieve statistical signiﬁcance (one
tailed t-test, P = .057).
T h ep o s i t i v ep r e d i c t i v ev a l u e so fA N C At e s t i n gf o rA A V
were calculated, before and after separating inpatients from
outpatients. Obtained results are shown in Table 4.I ti s
obvious that the combination of IIF and ELISA improved
diagnostic accuracy, compared to either IIF or ELISA alone.
The PPV of a combined IIF plus MPO/PR3 ELISA test was
estimated 84.5%. On the contrary, when IIF and MPO/PR3
ELISA were considered separately, the respective PPVs were
signiﬁcantly lower(20.6%and 74.1%).Exceptforthe PPV of
p-ANCA pattern that was very low both in inpatients and in
outpatients(14.6% and 17.8%, resp.), the outpatients’group
corresponded to higher rates of true positive results than any
other test combination.
4.Discussion
Several studies underline the diagnostic value of antineu-
trophil cytoplasmic antibodies, introducing them as a sig-
niﬁcant serological marker for a subset of patients with
primary systemic vasculitis. However, the predictive values
of ANCA testing for vasculitides in most reports range
widely, depending on the test characteristics of the assays
used and also on the patient populations studied. The
present work summarizes the experience of a 3-year periodAutoimmune Diseases 5
Table 3: Relationship between the results of ANCA testing and clinical diagnoses.
Diseases p-ANCA c-ANCA x-ANCA IIF (−)/ELISA (+) Anti-MPO (+) Anti-PR3 (+) Total (N)
MPA N 45 4 6 6 46 10 61
% 73.8 6.6 9.8 9.8 75.4 16.4
WG N 63 41 5 4 4 0 46
% 13.0 73.9 2.2 10.9 8.7 87
CSS N 402 0 6 0 6
% 66.7 0.0 33.3 0.0 100 0.0
CTD N 97 2 31 2 9 1 132
% 73.5 1.5 23.5 1.5 6.8 0.7
GD N 67 10 40 0 1 8 117
% 57.3 8.5 34.2 0.0 17.9 7.7
Other vasculitides N 27 1 11 0 7 3 39
% 69.2 2.6 28.2 0.0 5.6 0.0
Infections N 23 1 12 0 2 0 36
% 63.9 2.8 33.3 0.0 5.6 0.0
ND N 23 1 9 0 0 0 33
% 69.7 3.0 27.3 0.0 0.0 0.0
Malignancies N 21 1 9 0 1 0 31
% 67.7 3.3 29.0 0.0 3.3 0.0
RD N 18 0 4 0 2 0 22
% 81.8 0.0 18.2 0.0 9.0 0.0
Medication N 10 0 5 0 0 0 15
% 66.7 0.0 33.3 0.0 0.0 0.0
Miscellaneous disorders N 526 1 0 1 14
% 35.7 14.3 42.9 7.1 0.0 7.1
Undeﬁned diagnosis N 63 4 39 3 2 3 109
% 57.8 3.7 35.8 2.7 1.8 2.7
MPA: microscopic polyangiitis,WG: Wegener’s granulomatosis,CSS: Churg-Strausssyndrome, CTD: connective tissuediseases,GD: gastrointestinaldiseases,
ND: neurological diseases,RD: renal diseases.
Table 4: Positive predictive values (PPV) of ANCA testing for AAV.
Immunological marker All patients PPV% (95%CI) Inpatients PPV% (95%CI) Outpatients PPV% (95%CI)
p-ANCA 13.0 (9.5–16.6) 14.6 (9.8–19.4) 17.8 (11.5–24.2)
c-ANCA 67.9 (55.6–80.1) 57.9 (42.2–73.6) 88.8 (74.4–100)
p-ANCA plus c-ANCA 20.6 (16.7–24.6) 21.3 (16.2–26.4) 25.9 (19.1–32.8)
Anti-MPO 71.7 (61.8–81.8) 67.4 (53.8–80.9) 78.1 (63.8–92.4)
Anti-PR3 76.9 (66.7–87.2) 69.4 (54.4–84.5) 86.2 (73.7–98.8)
Anti-MPO plus anti-PR3 74.1 (66.9–81.3) 68.3 (58.2–78.4) 81.9 (72.3–91.6)
p-ANCA/MPO 80.3 (70.4–90.3) 77.7 (64.2–91.4) 84.0 (69.6–98.4)
c-ANCA/PR3 90.5 (81.6–99.4) 84.6 (70.7–98.5) 100
p-ANCA/MPO plus c-ANCA/PR3 84.5 (77.5–91.5) 80.6 (70.8–90.5) 90.2 (81.2–99.3)
from the largest hospital of Athens, providing data for
a cohort of 10803 unselected consecutive Greek patients.
This is the ﬁrst large retrospective study assessing ANCA
testing in Greek population. Both inpatients (6017) from
several diﬀerent departments and outpatients (4786) were
included to avoid selection bias and better reﬂect ANCA
test, requesting in routine clinical practice. Noteworthy,
the clinical information was obtained retrospectively, and
an u m b e ro fc a s e sw i t hi n s u ﬃcient data were excluded from
the results evaluation.
Several publications reveal diﬀerences in the genetic
proﬁle of Greek patients with autoimmune diseases [9–11].
Bokietal.intheirstudyof66Greekpatientswithnecrotizing
vasculitis did not ﬁnd any signiﬁcant associations of HLA-
class I and II alleles with PAN and CSS. In WG patients,
an increased frequency only in HLA-DR1 achieved statistical
signiﬁcance [12]. These ﬁndings are inconsistent with pre-
vious reports supporting that WG in Germany is associated
with HLA-DPB1∗0401, whereas CSS in Italy is associated
with HLA-DRB3 and HLA-DRB4 [8]. Since genetic and6 Autoimmune Diseases
environmental factors are implicated in the production of
ANCA, diﬀerences in distribution or magnitude of these
factors may inﬂuence the epidemiology of ANCA-associated
disorders in various populations.
Sch¨ onermark et al. have reported high rates (13.5%) of
IIFpositivityinpatientswithrheumatologicaldisorders[17].
Morethan halfofthesepatients(58.3%)hadaﬁnaldiagnosis
of AAV. On the other hand, signiﬁcantly lower rates of IIF
positivity (4.8–13%) were noted in less selected groups of
patients [13, 16, 19]. McLaren et al. found a wide variation
in diagnostic yield of ANCA among diﬀerent departments
(2–18%) of UK hospitals [14]. Of these patients, 0–56% had
conﬁrmed AAV. Our data showed that the yield of a positive
test by IIF was low (6%) and only 20.5% of ANCA positive
results were correlated with AAV. It was also shown that the
frequency of anti-MPO antibodies among p-ANCA positive
sera and the frequency of anti-PR3 antibodies among c-
ANCA positive sera was lower (16.1% and 68.3%, resp.),
comparedtopreviousreports[14,17].Theseﬁndings mirror
the highly heterogeneous population studied, the variety of
diseasesthatmaymimicvasculitidesandthediﬀerentclinical
practices among the diverse groups of physicians ordering
the tests.
Concerning ANCA speciﬁcity, present data conﬁrm
their high association with AAV (93.8%), especially of c-
ANCA/anti-PR3withWG(73.9%)andtoalesserextentofp-
ANCA/anti-MPO with MPA (67.2%). Anti-PR3 antibodies
were detected in 87% of WG patients and in 16.4% of MPA
patients. Anti-MPO antibodies were found in 75.4% of MPA
patients, in 8.7% of WG patients and in 100% of CSS cases
(all 5 patients studied). These ﬁndings are consistent with
previous reports in Europe [46]. On the other hand, reports
from China suggest that MPO-ANCA positive WG cases
are very common (60.7% [47]. In the present study, MPA
predominated among AAV patients. This ﬁnding conﬁrms
that in Europe, WG appears to be more common at high
latitudes, whereas MPA shows the reverse pattern [48].
In the present study, connective tissue diseases and
gastrointestinal disorders mainly constituted the non-AAV
group that predominated among ANCA positive patients,
followed by several other conditions including infections,
other vasculitides, medication, neurological diseases, renal
diseases and malignancies. Our data demonstrate that low
IIF titers and ELISA levels as well as low prevalence of anti-
MPO and anti-PR3 antibodies characterized these disorders.
Several reports support the high speciﬁcity of anti-MPO
and anti-PR3 antibodies for AAV, indicating that other
constituents of the primary granules of neutrophils might
be the target antigens of ANCA in non-AAV conditions
[6, 20, 21]. Testing for antibodies to these antigens could be
very helpful in the diagnostic approach of these diseases.
Apart from AAV, anti-MPO or anti-PR3 antibodies
have been also reported in other disorders [49–55]. These
disorders should be carefully ruled out when considering an
AAV diagnosis. In the present study, the anti-MPO group
included patients with secondary and undeﬁned vasculitis,
RA, SLE, AIH, TBC, PSGN, Goodpasture’s disease, and
multiple myeloma. The anti-PR3 group included patients
with IBD(mainlyUC),othervasculitides,SLE,psoriasis, and
AHA.
How conﬁdent can a clinician be that an ANCA positive
patient is an AAV patient? The positive predictive value
(PPV) of ANCA testing for AAV can answer this question.
Our results demonstrated that combined testing with IIF
plus PR3/MPO ELISA increased the PPV of ANCA for
AAV from 20.6% to 84.5%. This ﬁnding conﬁrms that the
combination of IIF with ELISA is more helpful than either
IIF or ELISA alone in the diagnostic approach of MPA, WG,
and CSS patients. However, higher PPVs of antineutrophil
cytoplasmic antibodies testing for AAV, especially of IIF
results (55–59%), have been reported [13, 14]. Since the
predictive value of any laboratory test depends on the
prevalenceofthedisease inthepopulationunderstudy,these
diﬀerences on PPV imply the low pretest probability of AAV
in the present clinical setting.
As i g n i ﬁ c a n td i ﬀerence in PPV of ANCA testing for AAV
was observed after separating outpatients from inpatients.
The group of outpatients yielded lower rates of false-positive
results (higher PPVs) when compared to the inpatients’
group. This variation in the diagnostic yield was likely based
on diﬀerences in clinical practice and in the composition of
the tested populations. Asigniﬁcant number of AAV patients
visit outpatient’clinics for a followup, leading to higher rates
oftrue positive results. Onthe otherhand, ahigh proportion
ofinpatientsundergoANCAtestingforawiderangeofother
ANCA-associated conditions.
Several reports have stated that the combination of IIF
plus antigen-speciﬁc ELISA, provides higher sensitivity and
speciﬁcity than either assay used separately [14, 56]. Since,
parallel IIF/ELISA testing is time consuming and expensive
and most ELISA assays have a lower sensitivity than IIF,
IIF is recommended as a screening method and ELISA as a
conﬁrmatory method [57–59]. However, various alternative
strategies on ANCA detection that include IIF, solid phase
MPO/PR3 ELISA and capture ELISA assays have been
reported to provide diagnostic accuracy [15, 60, 61]. In our
department, two diﬀerent algorithms on ANCA detection
have been implemented. All outpatients undergo testing by
IIFplusELISA,whereasallinpatientsareinitiallyscreenedby
IIF followed by ELISAin positive results. Asit was previously
mentioned, ANCA testing is also useful for the diagnosis
of a number of non-AAV disorders. Since the majority of
these disorders are not associated with anti-MPO or anti-
PR3, reported algorithms that use a sensitive ELISA at the
initial stage and proceed to IIF for conﬁrmation of positive
results cannot be applied.
A substantial decrease in the total cost of ANCA testing
would be expected for outpatients if ELISA was applied
in only IIF positive sera. By this strategy, among 4786
outpatients, only 17 IIF negative/ELISA positive cases would
have been missed. Of these, 3 represented ﬁrst diagnosed
AAV, while 8 had an already established AAV diagnosis, 3
represented non-AAV disorders (SLE, psoriasis, AHA) and
in 3 cases the ﬁnal diagnosis was undeﬁned. Based on
these data, it could be suggested that screening by IIF and
conﬁrming only IIF positive results by ELISA, in all patients,
would lead to substantial labor savings without sacriﬁcingAutoimmune Diseases 7
IIF
Clinical suspicion (CS) of 
ANCA associated diseases
MPO/PR3
ELISA 
Positive
Stop
ANCA
testing
Negative
High CS of AAV
Probable AAV Probable non AAV
Negative
Positive
High CS of AAV
Assess clinic-
pathological data
Figure 1: Algorithm on ANCA testing.
diagnostic accuracy. However, in cases where a high clinical
suspicion index for AAV remains, despite a negative IIF
result, ELISA test requesting should not be discouraged.
To summarize, thepresent reportthathighlighted ANCA
testing in a Greek Hospital under actual routine conditions
showed that (i) a large number of false positive ANCA
test results, especially by IIF, are to be expected in highly
heterogeneous groups of patients (ii) the non-AAV group
that was mainly represented by connective tissue diseases
and gastrointestinal disorders displayed very low rates of
MPO/PR3 ELISA positivity, (iii) since AAV are closely
associated with MPO/PR3 ANCA, the combination of IIF
and MPO/PR3 ELISA maximizes the diagnostic value of
ANCA testing, (iv) parallel testing with both IIF and ELISA
did not seem to oﬀer any signiﬁcant diagnostic advantages,
(v)screeningbyIIFandconﬁrmingpositiveresultsbyELISA,
results in substantial laboratory and cost eﬃciency, (vi)
assessment of clinicopathological data and compliance with
test-ordering guidelines will facilitate the interpretation of
test results and the diagnostic approach of patients with
ANCA-associated disorders.
In conclusion, based on our data we suggest that ANCA
testing should be restricted in patients with clinical picture
consistent with ANCA-associated diseases (e.g., AAV, Good
pasture’sdisease,IBD,AIHandPSC),followingtheproposed
algorithm (Figure 1). This rational use of ANCA testing can
reduce the total number of tests performed, minimizing
false positive results and laboratory charges and prevent
unnecessary and potentially harmful diagnostic and the
rapeutic procedures.
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